About
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Current Value
$3.321 Year Return
Current Value
$3.321 Year Return
Key Details
Market Cap
$310.99M
P/E Ratio
-0.79
1Y Stock Return
34.48%
1Y Revenue Growth
-77.06%
Dividend Yield
-
Price to Book
1.5
Strategies that include AMLX
Double maintains 1 strategies that include AMLX - Amylyx Pharmaceuticals, Inc.
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to AMLX
The stocks that are correlated to AMLX - Amylyx Pharmaceuticals, Inc. are CRBU, RGNX, ACLX, CRSP, DNLI
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 42.78% | $73.01M | -82.71% | 0.00% | |
R RGNXREGENXBIO, Inc. | 42.02% | $334.07M | -65.17% | 0.00% |
A ACLXArcellx, Inc. | 41.88% | $3.43B | +0.69% | 0.00% |
| 39.44% | $2.80B | -49.80% | 0.00% | |
| 39.42% | $1.86B | -32.65% | 0.00% | |
| 38.44% | $592.86M | -77.74% | 0.00% | |
| 38.38% | $210.72M | -67.99% | 0.00% | |
| 37.56% | $77.93M | -90.24% | 0.00% | |
| 37.48% | $1.66B | -53.81% | 0.00% | |
| 37.38% | $1.11B | -17.36% | 0.00% | |
| 36.96% | $713.23M | -72.41% | 0.00% | |
| 35.48% | $1.07B | -76.10% | 0.00% | |
C CMPSCompass Pathways Plc | 35.39% | $194.00M | -71.12% | 0.00% |
| 35.13% | $7.14B | -13.03% | 0.00% | |
I IMNMImmunome, Inc. | 35.08% | $542.57M | -69.20% | 0.00% |
B BLNKBlink Charging Co. | 35.03% | $89.17M | -68.18% | 0.00% |
| 34.96% | $2.69B | -38.11% | 0.00% | |
| 34.91% | $2.59B | -16.13% | 8.36% | |
T TZOOTravelzoo Inc. | 34.71% | $139.89M | +26.42% | 0.00% |
N NNOXNano-X Imaging Ltd. | 34.66% | $273.20M | -57.04% | 0.00% |
ETF's related to AMLX
The ETFs that are correlated to AMLX - Amylyx Pharmaceuticals, Inc. are XBI, GNOM, KOMP, PINK, IWC
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
X XBISPDR Biotech ETF | 47.11% | $5.06B | 0.35% |
| 45.14% | $48.48M | 0.5% | |
| 42.81% | $1.98B | 0.2% | |
| 42.80% | $141.74M | 0.5% | |
| 42.73% | $809.63M | 0.6% | |
| 42.58% | $987.53M | 0.75% | |
| 41.89% | $3.78B | 0.4% | |
| 41.00% | $5.70B | 0.45% | |
| 40.32% | $10.93B | 0.24% | |
| 40.10% | $16.19B | 0.04% | |
| 40.05% | $2.53B | 0.2% | |
| 39.66% | $17.62B | 0.07% | |
A ARKKARK Innovation ETF | 39.65% | $5.16B | 0.75% |
| 39.49% | $20.26B | 0.05% | |
| 39.44% | $11.24B | 0.07% | |
| 39.19% | $1.79B | 0.17% | |
| 39.14% | $169.45M | 0.79% | |
| 39.09% | $1.12B | 0.31% | |
| 39.07% | $63.84B | 0.19% | |
| 38.98% | $34.93M | 0.68% | |
News
Yahoo
We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) stands against other hot biotech stocks under $5. The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. After a […]
Yahoo
As of March 2025, the U.S. stock market has experienced a surge, driven by positive developments such as a temporary reprieve from tariffs impacting automakers, which led to gains in major indices like the Dow Jones Industrial Average and S&P 500. For investors seeking opportunities beyond well-known companies, penny stocks remain an intriguing option. Despite their vintage label, these stocks can offer significant growth potential when backed by strong financials and sound fundamentals. In...
Yahoo
Amylyx Pharmaceuticals Inc (AMLX) showcases promising clinical developments and a robust cash position, despite challenges in niche markets.
SeekingAlpha
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ETCompany ParticipantsLindsey Allen - Head of Investor...
Yahoo
CAMBRIDGE, Mass., March 04, 2025--Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Yahoo
CAMBRIDGE, Mass., February 25, 2025--Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds